𝘐𝘯𝘥𝘪𝘢'𝘴 𝘧𝘪𝘳𝘴𝘵-𝘦𝘷𝘦𝘳 𝘗𝘭𝘢𝘵𝘦𝘭𝘦𝘵-𝘙𝘪𝘤𝘩 𝘗𝘭𝘢𝘴𝘮𝘢 (𝘗𝘙𝘗) 𝘎𝘶𝘪𝘥𝘦𝘭𝘪𝘯𝘦𝘴 𝘓𝘢𝘶𝘯𝘤𝘩𝘦𝘥 𝘢𝘵 "𝘙𝘦𝘎𝘦𝘯 2025" 𝘊𝘩𝘦𝘯𝘯𝘢𝘪 𝘊𝘰𝘯𝘧𝘦𝘳𝘦𝘯𝘤𝘦
Chennai, 02 August 2025: The second edition of ReGen 2025, a two-day international conference on regenerative medicine, orthobiologics, pain management, and sports injury rehabilitation, commenced today in Chennai, drawing over 500 healthcare professionals from across India and abroad. The event marked a significant milestone in India’s medical landscape with the launch of the country’s first-ever Platelet-Rich Plasma (PRP) Guidelines, a standardised, evidence-based framework for PRP therapy, a transformative blood-based treatment for orthopedic, sports-related, and degenerative conditions.
 |
| (L to R) Dr. Sharmila Tulpule, Consultant Orthopedic Surgeon & Regenerative Medicine Specialist and Founder Director - Orthobiologix Clinic, and the Chairperson of ReGen 2025; Dr. G. K. Kumar, Professor and Head, Department of Anesthesia & Pain Medicine, Tamil Nadu Government Multi Super Speciality Hospital, Chennai; Niteen Tulpule, Co-Founder & Director, Orthobiologix Biotech Pvt. Ltd; Dr A Navaladishankar, Senior Consultant Orthopaedic Surgeon, Apollo Hospital Chennai |
Regenerative Medicine is a field of medicine that focuses on repairing, regenerating, or replacing damaged cells, tissues, or organs using the body’s natural healing processes. PRP therapy uses a concentrated dose of a patient’s own platelets to accelerate healing of injured tissues. The conference featured more than 60 speakers and panellists, including global stalwarts in regenerative medicine, and hosted over 25 high-impact plenary and interactive sessions on various aspects of regenerative medicine, which focuses on harnessing the body’s natural healing abilities to repair or replace damaged cells, tissues, and organs with growing promise across orthopedic, neurological, and musculoskeletal applications.
Press meet Youtube video Link 👇
In his address, Dr A Navaladishankar, Senior Consultant Orthopaedic Surgeon, Apollo Hospital Chennai, said, “The release of these PRP guidelines at ReGen 2025 is not just a scientific achievement. It’s a rallying point for India’s entire regenerative medicine ecosystem. With our vast clinical expertise and growing patient base, India is uniquely positioned to lead in the global regenerative movement. These guidelines lay the foundation for safe, standardised, and evidence-based care. We urge clinicians, researchers, and policymakers to embrace this moment as a turning point in how we approach healing and patient care.”
Talking about the conference, Mr. Niteen Tulpule, Co-Founder & Director, Orthobiologix Biotech Pvt. Ltd,, said, “The topics covered included cutting-edge regenerative procedures and technologies, including autologous blood products, which are therapies derived from the patient’s own blood to stimulate healing; allogenic cell therapy, which refers to the use of donor cells to repair or regenerate tissue; growth factor therapies that are applications of bioactive proteins to promote tissue regeneration, and bone marrow aspirate concentrate, a potent source of stem cells used in musculoskeletal and cartilage repair.
In his comments, Dr. G. K. Kumar, Professor and Head, Department of Anesthesia & Pain Medicine, Tamil Nadu Government Multi Super Speciality Hospital, Chennai, said, “The launch of India’s first-ever PRP guidelines marks a turning point for regenerative medicine in the country.
In her comments at the inaugural session of the conference, Dr. Sharmila Tulpule, Consultant Orthopedic Surgeon & Regenerative Medicine Specialist and Founder Director - Orthobiologix Clinic, and the Chairperson of ReGen 2025 said, “We are proud to host ReGen 2025, a landmark gathering that brings together some of the brightest minds in regenerative medicine from India and across the world.
****
